Cargando…
Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
OBJECTIVE: To report 3 patients with relapsing-remitting multiple sclerosis (RRMS) showing vitiligo after treatment with alemtuzumab. METHODS: Retrospective case series including flow cytometric analyses and T-cell receptor (TCR) sequencing of peripheral blood mononuclear cells. RESULTS: We describe...
Autores principales: | Ruck, Tobias, Pfeuffer, Steffen, Schulte-Mecklenbeck, Andreas, Gross, Catharina C., Lindner, Maren, Metze, Dieter, Ehrchen, Jan, Sondermann, Wiebke, Pul, Refik, Kleinschnitz, Christoph, Wiendl, Heinz, Meuth, Sven G., Klotz, Luisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329330/ https://www.ncbi.nlm.nih.gov/pubmed/30404783 http://dx.doi.org/10.1212/WNL.0000000000006648 |
Ejemplares similares
-
Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019) -
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021) -
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019) -
Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021) -
Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)